Collplant Biotechnologies LtdNASDAQ:CLGN
- LAST PRICE4.8531
- TODAY'S CHANGE (%)-0.1469 (-2.9380%)
- Bid / Lots3.5000/ 1
- Ask / Lots7.7700/ 2
- Open / Previous Close5.0000 / 5.0000
- Day Range
- 52 Week Range
- Volume8,381
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLGN |
|---|---|---|
| 09:59 ET | 500 | 5 |
| 02:18 ET | 283 | 4.8969 |
| 02:44 ET | 200 | 4.8401 |
| 02:45 ET | 3199 | 4.8337 |
| 02:54 ET | 176 | 4.68 |
| 02:58 ET | 500 | 4.53 |
| 03:39 ET | 200 | 4.7207 |
| 03:48 ET | 1000 | 4.8561 |
| 03:50 ET | 1000 | 4.8599 |
| 03:56 ET | 110 | 4.73 |
| 03:57 ET | 1000 | 4.8531 |
Aug 21, 2024
DJ Collplant Biotechnologies Price Target Maintained With a $11.00/Share by HC Wainwright & Co., from 8:50AM ET on Wednesday Aug 21, 2024 by Dow Jones
8:50AM ET on Wednesday Aug 21, 2024 by Dow Jones
Aug 20, 2024
DJ Collplant Biotechnologies Is Maintained at Buy by EF Hutton, from 12:38PM ET on Tuesday Aug 20, 2024 by Dow Jones
12:38PM ET on Tuesday Aug 20, 2024 by Dow JonesCOLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE, from 7:00AM ET on Tuesday Aug 20, 2024 by Dow Jones
7:00AM ET on Tuesday Aug 20, 2024 by Dow JonesPress Release: COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE, from 7:00AM ET on Tuesday Aug 20, 2024 by Dow Jones
7:00AM ET on Tuesday Aug 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Collplant Biotechnologies Ltd | 57.3M | -3.2x | --- |
Syros Pharmaceuticals Inc | 53.1M | -0.5x | --- |
Affimed NV | 60.6M | -0.7x | --- |
Atara Biotherapeutics Inc | 48.7M | -0.2x | --- |
DURECT Corp | 48.4M | -2.7x | --- |
Curis Inc | 35.1M | -0.7x | --- |
Company Information
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Contact Information
- Headquarters
- 4 Oppenheimer Street, P.O. Box 4132REHOVOT, Israel 7670104
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Roger Pomerantz
- Chief Executive Officer
- Yehiel Tal
- Deputy Chief Executive Officer, Chief Financial Officer
- Eran Rotem
- Chief Operating Officer
- Ilana Belzer
- Vice President - Human Resources
- Hadas Dreiher Horowitz
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $57.3M |
|---|---|
Revenue (TTM) | $689.0K |
Shares Outstanding | 11.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-1.53 |
Book Value | $2.47 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 83.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,671.26% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
